OBJECTIVE To compare the efficacy and adverse effects of PUVA vs NBUVB in early-stage MF. STUDY SELECTION Studies of cohorts with histologically confirmed early-stage MF, defined as stages IA, IB, and IIA, that compared PUVA vs NBUVB, had at least 10 patients in each comparator group, and reported outcomes of response to therapy. Exclusion criteria were studies with patients with stage IIB or higher MF, pediatric patients, fewer than 10 in each comparator group, noncomparative studies, case reports, and abstract studies.
M ycosis fungoides (MF) is a form of cutaneous T-cell lymphoma (CTCL) that follows an indolent clinical course in most cases. It is a form of non-Hodgkin lymphoma characterized in its early stages by papulosquamous patches or plaques, which can rarely progress to become tumors with involvement of the lymphatic system and other viscera. Most patients have early-stage MF (stages IA-IIA), which is associated with a favorable prognosis. Skin-directed therapies are used as first-line treatment, including topical corticosteroids, topical chemotherapeutic agents, topical and systemic retinoids, methotrexate, and phototherapy. For patients with advanced-stage MF or Sézary syndrome (stages IIB-IVB), disease is often recalcitrant to treatment and more aggressive modalities, such as chemotherapy, radiotherapy, extracorporeal photopheresis, and allogenic hematopoietic stem cell transplant, may be required. 1, 2 Phototherapy is one of the mainstays of treatment for patients with early-stage MF. The most commonly used modalities are narrowband UV-B (NBUVB) radiation, which involves UV irradiation at a wavelength of 311 nm or psoralen-UV-A (PUVA) phototherapy, involving UV irradiation ranging from 320-340 nm in combination with systemic or topical psoralen. Psoralen-UV-A and NBUVB have different electromagnetic and biological properties and underlying mechanisms of action. Given its longer wavelength, UV-A radiation is capable of penetrating deeper within the dermis, and this is thought to contribute to better response initially and prolonged disease-free periods. As such, PUVA may be more suited for patients with thick plaques or those recalcitrant to NBUVB therapy. The psoralen in PUVA also directly interacts and damages DNA, generating oxygen-free radicals, which damage cell organelles. [3] [4] [5] UV-A has also been hypothesized to trigger apoptosis cascades via p53-independent programmed cell death mechanisms. 3, 4 Phototoxic effects of PUVA have been shown to selectively target neoplastic T lymphocytes in the skin. 3, 6, 7 The mechanisms of UV-B therapy in MF are less clear; however, they are thought to involve interference with immunity via Langerhans cells. The cells' antigen presentation capacity is inhibited, and cytokines interleukin (IL)-2, IL-6, and tumor necrosis factor are upregulated. 4, 8 In addition, T-cell apoptosis may be involved, suppressing neoplastic activity in MF. 9 Although both PUVA and NBUVA have been widely used during the past several decades, the volume of noncomparative data to evaluate their efficacy in inducing disease response in early-stage MF is small. In recent years, NBUVB has become popular given reports of similar efficacy to PUVA but with fewer adverse effects and lesser risk of carcinogenesis. [10] [11] [12] Narrowband UV-B radiation has been associated with reduced erythema and irritation compared with broadband UV-B, thus requiring a reduced lesion clearance dose in the context of inflammatory skin disorders such as psoriasis. 10, 13, 14 However, whether these benefits are relevant to MF is yet to be demonstrated because there has been limited evidence from direct comparison of these 2 forms of phototherapy. In addition, associations between MF stages or lesion types and phototherapy outcomes have not been well studied. To our understanding, there has been no meta-analysis directly comparing PUVA and NBUVB in the treatment of earlystage MF. Therefore, to evaluate the relative benefits and risks of PUVA vs NBUVB therapy, we conducted a systematic review and meta-analysis of the available comparative literature.
Methods

Search Strategy
We performed a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline to investigate the efficacy and safety of PUVA vs NBUVB in patients with early-stage MF. Electronic searches were performed using Ovid Medline, PubMed, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, American College of Physicians Journal Club, and Database of Abstracts of Review of Effectiveness from their dates of inception to March 30, 2018. To achieve the maximum sensitivity of the search strategy, we combined the terms UV A, PUVA, mycosis fungoides, Sézary syndrome, cutaneous T-cell lymphoma, UV B, and UVB as either key words or MeSH terms (eTable in the Supplement). The reference lists of all retrieved articles were reviewed to further identify potentially relevant studies, and our inclusion and exclusion criteria were applied.
Selection Criteria
Eligible studies for the systematic review and meta-analysis included those in which cohorts of patients who underwent PUVA phototherapy were compared directly with cohorts of patients who underwent NBUVB phototherapy. Inclusion criteria were cohorts with histologically confirmed early-stage MF (defined as stages IA to IIA), comparison of PUVA (bath or oral) with NBUVB, at least 10 patients in each comparator group, and outcomes of response to therapy. Exclusion criteria were studies of stage IIB and higher (tumors, erythroderma, or lymph node involvement requiring systemic agents were not investigated in this meta-analysis), cohorts including pediatric patients, fewer than 10 patients in each comparator group, noncomparative studies, case reports, and abstract studies. Language was not an exclusion criterion.
resolved by discussion and consensus. If the study provided medians and interquartile ranges (IQRs) instead of means and SDs, we imputed the means and SDs as described by Hozo et al. 15 If Kaplan-Meier graphs were provided but not the hazard effect or 95% CI, these were estimated using methods by Tierney et al. 16 Quality appraisal of studies was assessed using the Cochrane Collaboration tool for assessment.
Statistical Analysis
Odds ratios (ORs) were used as summary statistics. A randomeffects model was used to take into account the possible clinical diversity and methodological variation among studies. To study heterogeneity between trials, we used χ2 tests. We used the I 2 statistic to estimate the percentage of total variation across studies owing to heterogeneity rather than chance, with values greater than 50% considered as substantial heterogeneity; I 2 can be calculated as I 2 = 100 × [(Q-df)/Q], with Q defined as the Cochrane heterogeneity statistic. If there was substantial heterogeneity, the possible clinical and methodological reasons for this were determined qualitatively by subgroup analysis. Specific analyses considering confounding factors were not possible because raw data were not available. All P values were 2-sided, and statistical significance was set at P < .05. All statistical analysis was conducted with Review Manager, version 5.3 (Cochrane Collaboration, Software Update).
Results
Search Results
A total of 438 references were identified through electronic database searches. After exclusion of duplicate or irrelevant references, 374 potentially relevant articles were retrieved. After applying the selection criteria, 7 articles were selected for analysis (eFigure 1 in the Supplement). [17] [18] [19] [20] [21] [22] [23] The study and baseline characteristics of these studies are summarized in Table 1 and Table 2 . There were a total of 527 patients treated with PUVA compared with 251 treated with NBUVB. All studies were retrospective observational studies except for El-Mofty et al, 20 which was a prospective study. Study appraisal is summarized in eFigure 2 in the Supplement. The majority of included studies were of poor to moderate quality, with the major common critiques including lack of random sequence generation, lack of allocation concealment, lack of blinding of participants and personnel, and lack of blinding of outcome assessment.
Baseline Patient Characteristics
The mean age of the 527 patients who underwent PUVA ranged from 33 to 70 years, and the mean age of the 251 patients who were treated with NBUVB ranged from 33 to 68 years. A total of 292 of 501 (58.3%) of the patients treated with PUVA were male compared with 113 of 223 (50.7%) in the NBUVB cohort, which was not significantly different (P = .14). Nikolaou et al. 21 When pooled, PUVA was associated with significantly higher hazard ratio of freedom from recurrence compared with NBUVB (hazard ratio, 1.93; 95% CI, 1.07-3.49; P = .03) (Figure 3) . Heterogeneity: τ 2 = 0.00; χ 2 = 2.53; df = 4; P = .64; I 2 = 0% Test for overall effect: z = 2.41 (P = .02)
Test for subgroup differences: χ 2 = 1.02; df = 2; P = .60; I 2 = 0%
A random-effects Mantel-Haenszel model was used. Squares represent mean values with error bars representing 95% CIs; diamonds, pooled means with the 95% CIs at the points. OR indicates odds ratio. Although both PUVA and NBUVB seem to be well tolerated, adverse effects associated with PUVA have been reported in the literature. The photosensitizing agent psoralen has been linked with nausea, vomiting, headache, phototoxic effects, and photoimmune suppression. 26 The carcinogenic risk of PUVA has also been reported to be greater compared with NBUVB. 12 In contrast, NBUVB has been associated with erythema, blistering, pruritus, xerosis, and herpes simplex virus reactivation. 27 Other advantages of NBUVB include convenience for patients because they do not need to take or bathe in psoralen and do not require UV protective glasses after treatment. The British Association of Dermatologists guidelines suggest using NBUVB for patch disease and PUVA for plaque disease. 28 Because NBUVB has proved to be effective in patchstage disease, it is the preferred modality in such cases owing to its less severe adverse effect profile. 28 However, NBUVB still has a role in plaque cutaneous T-cell lymphoma. Treatment with NBUVB is widely used for plaque MF in settings where PUVA is not readily available, and it may still be an effective therapeutic option as our review demonstrates. Furthermore, NBUVB is more widely available; is less demanding of patients because they are not required to take oral psoralen or psoralen baths or maintain absolute photoprotection after treatments as required with PUVA; and is less likely to be associated with the development of cutaneous malignant neoplasm. 29, 30 The decision to select a type of irradiation treatment must not only balance risks and benefits but also involve consideration of factors such as stage or lesion, compliance, cost, availability, and ease of use.
31
Limitations
The present meta-analysis is constrained by several limitations. First, the analysis does not adjust for potential confounders. Furthermore, articles used in the review stratified patients by stage of MF and classification of patch vs plaque disease, limiting interpretation of results. Heterogeneity in phototherapy techniques, including type of PUVA (bath vs oral), and protocol in terms of frequency of therapy and dose and duration, which varies from center to center, also undermines the validity of the results. Follow-up periods similarly varied from study to study, which limited assessment of major adverse effects after phototherapy. Pooled analysis does not account for differences in patient compliance to therapy, as well as baseline differences in patient characteristics including age, sex, comorbidities, and duration of disease before diagnosis and treatment. Included studies were predominantly observational and retrospective in nature and thus susceptible to selection bias. Randomized clinical trials would be ideal to negate this bias; however, we acknowledge the challenge of performing such studies of rare diseases such as MF. Overall the quality of evidence available was judged to vary from poor to moderate.
Conclusions
Based on limited evidence, our study suggests that PUVA may be an effective alternative to NBUVB for phototherapy for early-stage MF. This finding is in the context of the difficulty of performing randomized clinical trials for MF, which is a rare disease. Current results should be tempered by consideration of the adverse effect profile of both modalities.
